Postpartum Depression Signs: A Comprehensive Recognition Guide

Postpartum depression (PPD) is one of the most common and most under-recognised complications of childbirth, affecting approximately 10-15 percent of women globally and 11-22 percent of women in India per available studies. Three distinct mood conditions can occur in the postpartum period: "baby blues" (transient and normal, affecting most women), postpartum depression (clinical condition requiring treatment), and postpartum psychosis (rare but a psychiatric emergency). Distinguishing these conditions and recognising PPD signs early matters substantially because PPD is highly treatable but, when untreated, carries significant consequences for the mother, infant bonding, child development, and family functioning. This guide covers the signs and recognition of postpartum depression including the DSM-5 peripartum onset specifier, specific symptoms common in postpartum context, distinction from baby blues and postpartum psychosis, EPDS screening, paternal PPD, treatment overview including breastfeeding-compatible options, and India-specific context where joint family dynamics, cultural confinement periods, and stigma all affect recognition and help-seeking.

Three postpartum mood conditions

Three distinct conditions occur in the postpartum period; recognising the differences is essential for appropriate response.

What PPD is

Postpartum depression is a major depressive episode occurring during pregnancy or in the months following childbirth. Per DSM-5, the diagnosis is Major Depressive Disorder with "peripartum onset" specifier, where mood symptoms begin during pregnancy or within 4 weeks after delivery. In clinical practice and research, depression developing within 12 months postpartum is commonly considered postpartum depression, though DSM-5 strictly limits the specifier to 4 weeks postpartum.

The "peripartum" framing in DSM-5 reflects research showing that mood symptoms during pregnancy and postpartum share similar features, risk factors, and biological mechanisms. The earlier DSM-IV "postpartum onset" framing was extended to include pregnancy because mood disorders that begin during pregnancy often continue postpartum and are biologically related.

PPD meets standard MDD criteria (5 of 9 specific symptoms including depressed mood or anhedonia, present nearly every day for 2 weeks or longer, with substantial functional impairment) plus the timing relationship to pregnancy or childbirth. See our MDD guide for core depression criteria.

ICD-10 codes PPD typically as F32 (Depressive episode) or F33 (Recurrent depressive disorder) with the puerperium relationship noted in clinical documentation. F53.0 codes mild mental and behavioural disorders associated with the puerperium specifically, used in some clinical contexts.

PPD is highly treatable. With appropriate treatment, most women recover within 6-12 months; many recover faster. Without treatment, PPD typically persists 6-12 months or longer and carries substantial risks for the mother, infant bonding, child development, and family functioning. Recognition is the first step toward treatment.

DSM-5 criteria and peripartum onset

PPD diagnosis per DSM-5 requires:

1. Meeting criteria for major depressive episode: 5 or more of 9 specific symptoms present nearly every day for 2 weeks or longer, including either depressed mood or loss of interest/pleasure
2. The 9 MDD symptoms: depressed mood; loss of interest or pleasure; significant weight or appetite change; sleep disturbance; psychomotor changes; fatigue or loss of energy; worthlessness or excessive guilt; concentration difficulties; thoughts of death or suicide
3. Substantial functional impairment in social, occupational, or other important areas
4. Symptoms not attributable to substance or medical condition
5. Symptoms not better explained by other psychiatric condition
6. For "peripartum onset" specifier: onset of mood symptoms during pregnancy or within 4 weeks after delivery

The 4-week postpartum cutoff in DSM-5 is criticised by many clinicians and researchers as too restrictive; PPD onset within the first year is common and clinically meaningful regardless of formal DSM-5 specifier criteria. Many clinical guidelines (UK, USA, India) define PPD more broadly as depression occurring within 12 months postpartum.

The criteria allow PPD diagnosis during pregnancy as well as postpartum. Antenatal depression (during pregnancy) is sometimes considered separately from postnatal depression (after delivery), but both fall under the peripartum framing.

Signs of postpartum depression

PPD signs overlap with general depression with some context-specific features. The signs cluster into mood, bonding-related, physical, cognitive, and behavioural categories.

Symptoms typically develop gradually between 2 weeks and 6 months postpartum, but can begin during pregnancy or up to 12 months postpartum. The gradual onset means PPD can be missed by family members who attribute changes to normal new-parent fatigue. Persistent symptoms beyond 2 weeks warrant professional assessment.

Baby blues vs PPD comparison

If mood symptoms persist beyond 2 weeks, are severe, involve thoughts of harm to self or baby, substantially impair functioning, or include features of postpartum psychosis (delusions, hallucinations), this is more than baby blues and warrants professional assessment.

Onset timing

PPD onset timing varies substantially across patients:

• During pregnancy (antenatal or prenatal depression): approximately 10-15 percent of pregnant women experience depression during pregnancy. This often continues or worsens postpartum.
• First 2 weeks postpartum: distinguishing baby blues from emerging PPD can be difficult. Severe or persistent symptoms warrant assessment.
• 2 weeks to 4 weeks postpartum: within DSM-5 strict peripartum onset specifier window. Common onset period.
• 1-6 months postpartum: substantial proportion of cases develop during this period. Increasing infant care demands, returning to work, ongoing sleep deprivation, hormonal adjustment all contribute.
• 6-12 months postpartum: some cases continue to emerge. Returning to work, breastfeeding decisions, infant developmental milestones can be triggers.
• Beyond 12 months: mood disorders developing more than 12 months postpartum may not be classified as PPD but as general depression in a parent.

PPD can also be a continuation or worsening of pre-existing depression that began before pregnancy. Approximately 50 percent of women with a history of depression develop PPD. Pre-pregnancy depression history is one of the strongest PPD risk factors.

Risk factors

Causes and biological mechanisms

PPD develops through interaction of biological, psychological, and social factors:

Hormonal shifts. Pregnancy involves substantial increases in estrogen and progesterone; childbirth produces precipitous drops in these hormones, with estrogen dropping by approximately 100-fold in the days after delivery. These dramatic shifts affect neurotransmitter systems including serotonin, dopamine, and GABA pathways involved in mood regulation. Individual variation in sensitivity to these hormonal changes may explain why some women develop PPD while others do not.

HPA axis dysregulation. The hypothalamic-pituitary-adrenal axis is altered during pregnancy and recovery takes time. Cortisol regulation can remain disrupted for months postpartum.

Thyroid changes. Postpartum thyroiditis affects 5-10 percent of women in the first year postpartum; can cause hyperthyroid then hypothyroid phases. Symptoms overlap substantially with PPD; thyroid testing is part of PPD workup.

Sleep deprivation. Newborn care produces profound sleep disruption; sleep deprivation is independently associated with mood symptoms. The bidirectional relationship between sleep and mood compounds postpartum risk.

Inflammatory factors. Childbirth produces inflammatory changes; emerging research suggests inflammation may contribute to PPD in some women.

Genetic factors. Family history of mood disorders raises PPD risk. Specific genetic variants affecting hormonal sensitivity, neurotransmitters, and stress response are implicated.

Psychological factors. Identity shifts around motherhood; loss of pre-baby self; changes in relationship dynamics; perfectionism about parenting; childhood adversity history; insecure attachment patterns.

Social factors. Lack of social support is one of the strongest modifiable risk factors. Isolation, relationship problems, financial stress, and cultural pressures all contribute.

Postpartum psychosis

Symptoms of postpartum psychosis:

• Severe mood instability with rapid shifts between elation and depression
• Delusions (false fixed beliefs, often involving the baby, religious themes, or paranoid content)
• Hallucinations (hearing voices, seeing things, sometimes voices commenting on the mother or baby)
• Severe confusion or disorientation
• Bizarre behaviour or speech
• Severely disrupted sleep without fatigue (going 24+ hours without sleep without feeling tired)
• Thoughts of harming oneself or the baby (these require immediate emergency response)
• Inability to care for self or baby
• Rapidly worsening rather than stable symptoms

Risk factors for postpartum psychosis:

• History of bipolar disorder: 25-50 percent of women with bipolar experience postpartum psychosis
• Previous postpartum psychosis: 50 percent recurrence in subsequent pregnancies
• Family history of bipolar disorder or postpartum psychosis
• First pregnancy
• Discontinuation of mood stabilisers during pregnancy
• Sleep deprivation
• Severe complications during delivery

Why urgent response matters. Postpartum psychosis carries substantial suicide and infanticide risk; immediate intervention is essential. The mother should not be left alone with the baby. Immediate psychiatric assessment is required, typically in hospital setting. Treatment involves antipsychotic medication, mood stabilisers, sometimes ECT, and intensive monitoring. With appropriate treatment, prognosis is generally good and most women recover fully.

India access. Call Tele-MANAS 14416, KIRAN 1800-599-0019, or take the mother to the nearest hospital emergency. NIMHANS, AIIMS, and major government and private psychiatric services provide emergency assessment.

EPDS screening

The Edinburgh Postnatal Depression Scale (EPDS) is the most widely used screening tool for PPD. Developed by Cox, Holden, and Sagovsky in 1987, the EPDS has been validated in many languages including Hindi, Tamil, Telugu, Bengali, Marathi, Punjabi, and other Indian languages.

EPDS characteristics:

• 10 self-report items covering mood, anhedonia, anxiety, sleep, guilt, and suicidal thoughts
• Takes 5-10 minutes to complete
• Scored 0-30; higher scores suggest depression
• Cutoff 10 or higher: possible depression; further assessment warranted
• Cutoff 13 or higher: probable depression; clinical assessment recommended
• Question 10 specifically asks about thoughts of self-harm; any positive response warrants immediate follow-up
• Can be used during pregnancy and postpartum
• Available freely and validated in many languages

When EPDS should be administered:

• During pregnancy (at least once, typically third trimester)
• 6 weeks postpartum (typical first postnatal screening)
• 3-6 months postpartum (second screening)
• 12 months postpartum if symptoms emerge
• At any postpartum visit if symptoms are reported
• Pediatric visits provide opportunity for maternal screening

NICE guidance, WHO recommendations, and various Indian guidelines support routine EPDS screening in perinatal care. Implementation in India varies; routine screening at antenatal and postnatal visits is recommended but not universally practised.

EPDS is a screening tool, not a diagnostic instrument. Positive screen warrants clinical assessment by qualified mental health professional.

Postpartum thyroiditis

Postpartum thyroiditis affects approximately 5-10 percent of women in the first year postpartum. The condition typically follows a biphasic course: hyperthyroid phase first (usually 1-6 months postpartum), then hypothyroid phase (usually 3-12 months postpartum). Symptoms of both phases can mimic or contribute to PPD.

Hyperthyroid phase symptoms can include anxiety, irritability, insomnia, palpitations, heat intolerance, weight loss despite normal appetite, fatigue, tremor.

Hypothyroid phase symptoms can include depression, fatigue, weight gain, cold intolerance, constipation, hair loss, dry skin, slowed thinking.

Thyroid testing (TSH, T3, T4, and sometimes thyroid antibodies) should be part of PPD workup. Treating thyroid dysfunction may resolve mood symptoms; persistent depressive symptoms despite thyroid correction warrant continued PPD treatment.

Paternal postpartum depression

Paternal PPD is increasingly recognised but remains substantially under-discussed. Father involvement in infant care affects child development; paternal PPD impacts family functioning, the partner's recovery from her own PPD if present, and child outcomes.

Risk factors for paternal PPD:

• Partner has PPD (strongest predictor)
• Prior depression history
• Financial stress
• Relationship difficulties
• Lack of social support
• First-time parenthood
• Difficult infant temperament
• Sleep deprivation
• Identity changes around parenthood
• Limited paternity leave or work flexibility

Symptoms in fathers may differ from typical depression presentation: increased irritability and anger more prominent than visible sadness; withdrawal from family or work overinvestment; substance use; physical symptoms; risk-taking behaviours; sleep disturbance; sometimes anxiety more visible than depression.

Cultural pressures on fathers to be strong, provide, and "cope" can mask symptoms and delay help-seeking. In Indian context, traditional expectations of male strength and stoicism may particularly delay help-seeking; awareness is growing but remains limited.

Treatment principles for paternal PPD match standard depression treatment: psychotherapy, sometimes medication, lifestyle measures, family support.

Treatment overview

PPD treatment follows depression treatment principles with peripartum considerations.

Mild PPD: psychotherapy first-line; behavioural activation, Cognitive Behavioural Therapy (CBT), Interpersonal Therapy (IPT specifically adapted for postpartum has strong evidence); lifestyle measures including sleep optimisation where possible, physical activity, social connection; peer support groups; family involvement and education; reduced expectations on the mother during recovery.

Moderate to severe PPD: combination of psychotherapy plus antidepressant medication; SSRIs typical first-line. Sertraline (Zoloft) is particularly well-studied during breastfeeding and often first choice. Escitalopram, paroxetine, and other SSRIs also used. Medication takes 2-4 weeks to begin working, 6-8 weeks for full effect.

Severe PPD with suicide risk or psychotic features: hospitalisation may be needed; mother-baby psychiatric units (limited availability in India) ideal where available; ECT considered in severe cases including psychotic depression; antipsychotic medication for psychotic features; close monitoring including ensuring mother is not alone with baby in severe cases.

Treatment duration: typically 6-12 months after full recovery to reduce relapse risk. Some women benefit from longer treatment, particularly those with prior depression history.

Beyond standard treatment:

• Family education and partner involvement
• Support groups for postpartum mothers
• Sleep optimisation strategies including night-time support from partner or family
• Practical help with infant care and household tasks
• Addressing breastfeeding difficulties if relevant
• Treating coexisting conditions (anxiety, thyroid dysfunction, anaemia)
• Addressing relationship and social context contributors

Breastfeeding and medication

Breastfeeding considerations affect PPD medication decisions but should not prevent appropriate treatment.

Key principles:

• Most SSRIs are compatible with breastfeeding with minimal infant exposure
• Sertraline often preferred for first-time medication choice during breastfeeding (low milk transfer, well-studied, generally well-tolerated by infants)
• Escitalopram and other SSRIs also commonly used
• Paroxetine sometimes preferred during breastfeeding (low milk transfer) but generally less in pregnancy
• Fluoxetine has longer half-life and active metabolite; somewhat higher infant exposure but generally still considered compatible
• Consultation with psychiatrist and paediatrician helpful for specific medication decisions
• Untreated maternal depression carries substantial risks for both mother and baby; treatment is usually appropriate even during breastfeeding
• Mothers should not avoid treatment due to breastfeeding concerns alone without clinical discussion

Monitoring infants of breastfeeding mothers on antidepressants: for changes in sleep, feeding, weight gain, or general behaviour. Significant changes warrant medical review.

When breastfeeding compatibility is limited: some psychiatric medications have less safety data during breastfeeding. The decision balances maternal mental health needs and infant exposure; sometimes formula feeding may be appropriate to allow needed treatment. This decision should be made with full information from psychiatrist and paediatrician.

India context

PPD in Indian context has distinctive features:

Prevalence in India. Indian studies consistently report PPD prevalence at the higher end of or above global ranges, with most studies finding 11-22 percent rates. Some studies in low-income, rural, or high-stress settings report rates of 20-25 percent or higher. National Mental Health Survey of India (NMHS, 2015-16) and various smaller studies confirm PPD is a major public health issue. The treatment gap (proportion of affected women not receiving treatment) is severe, often exceeding 80 percent.

Cultural confinement period. Traditional postpartum practices in India typically include a confinement period (often 40 days, sometimes varying by tradition) during which the mother stays at home, often at her natal home, with restrictions on activity, visitors, and household roles. Family members provide intensive support. This period can be protective (extensive support, rest, infant care assistance) or contributing to PPD (isolation, restriction, conflict with caregivers, loss of autonomy). The cultural practice itself is not the issue; the relational quality and conflict potential within it matter.

Joint family dynamics. Joint family systems can substantially support new mothers (childcare help, household tasks, emotional support, intergenerational wisdom). They can also be sources of stress (mother-in-law conflicts, criticism, restrictive practices, son preference pressure, lack of autonomy). The effect on PPD depends on relational dynamics rather than family structure itself.

Son preference and gender pressure. Cultural pressure for son preference affects PPD risk. Mothers of female babies may experience reduced family support, criticism, or disappointment that contributes to depression. The 2011 Census and subsequent data show persistent gender ratio imbalances reflecting these pressures. Modern Indian families increasingly reject son preference, but the cultural undertow remains in many contexts.

Mother-in-law dynamics. The relationship between new mother and mother-in-law substantially affects postpartum experience. Supportive mother-in-law relationships protect against PPD; conflicted or critical relationships increase risk. Power dynamics around infant care decisions can create ongoing stress.

Working mothers in modern India. Urban professional mothers face particular pressures: short maternity leave, return-to-work timing, breastfeeding-work integration, childcare arrangements, financial responsibilities. These factors can contribute to PPD.

Stigma and recognition. Stigma against acknowledging mental distress during a culturally celebrated event (motherhood) substantially affects recognition and help-seeking in India. Mothers may feel they should be happy and grateful; admitting distress feels like failure or ingratitude. Family members may reinforce this framing by attributing symptoms to weakness, character flaws, or insufficient gratitude.

Access to care. NIMHANS, AIIMS, government district mental health programmes, and private psychiatric services provide perinatal mental health support. Tele-MANAS (14416) can guide to local services. Mother-baby psychiatric units are limited in availability. Routine perinatal mental health screening is not yet universal practice.

Indian perinatal psychiatric resources. NIMHANS perinatal psychiatry services in Bengaluru; AIIMS perinatal mental health programmes; various private psychiatric services with perinatal focus in major cities; some NGOs focused on maternal mental health. The infrastructure is growing but remains uneven.

When to seek help

Professional consultation is appropriate when:

• Mood symptoms persist beyond 2 weeks postpartum
• Mood symptoms during pregnancy that affect functioning
• Substantial impairment in self-care, baby care, or relationships
• Difficulty bonding with the baby that persists
• Intrusive thoughts about harm coming to the baby (warrant assessment even if not predictive of action)
• Thoughts of self-harm or suicide (immediate help)
• Concerns about ability to care for the baby
• Substance use accompanying mood symptoms
• Family or partner concerns about your wellbeing
• Symptoms continuing despite self-management measures
• Onset of psychotic symptoms (delusions, hallucinations, severe confusion): EMERGENCY
• Mother feels she cannot continue or wants to escape from the baby or family

First contact can be a GP, psychiatrist, obstetrician, or clinical psychologist. In India, Tele-MANAS (14416) provides 24x7 guidance. Pediatric visits also provide opportunity for maternal mental health discussion; many pediatricians screen for PPD or can refer.

A note from Dr. Boppana Sridhar

PPD is one of the most under-recognised mental health conditions in India. The reasons are cultural and structural: motherhood is celebrated, distress during this celebrated time is culturally difficult to acknowledge, joint family settings can both support and pressure, and routine perinatal mental health screening remains uneven. What I want patients and families to know is that PPD is not failure, weakness, or insufficient gratitude. It is a medical condition affecting 11-22 percent of Indian mothers based on available studies, with measurable biological changes following childbirth. Recognition is the first step; treatment is highly effective. Most women I have treated for PPD recover well with combined psychotherapy and medication; those who recognise symptoms early often recover faster and with fewer effects on bonding and child development. For families: please understand that PPD is real, that asking the new mother about her wellbeing is not insulting her but supporting her, and that early professional consultation is valuable. For fathers: paternal PPD is also real and treatable; please do not assume you should "be strong" through symptoms that warrant treatment. For mothers experiencing what may be PPD: you are not alone, this is treatable, and asking for help is a sign of strength and care for your family, not weakness. Tele-MANAS at 14416 is a good starting point if you do not know where to go.

Frequently asked questions

Related reading on 247healthcare.blog

• Mental Health and Primary Care: hub
• Depression and Mood Disorders: Pillar 2
• What is Major Depressive Disorder?
• Depression Symptoms in Adults
• MDD Diagnosis Guide
• Bipolar Disorder Symptoms and Mania
• Depression vs Sadness vs Grief
• Anxiety Disorders: Pillar 1

References

1. American Psychiatric Association. DSM-5 peripartum onset specifier.
2. NICE CG192. Antenatal and postnatal mental health: clinical management and service guidance.
3. WHO. Maternal mental health and child health and development guidance.
4. National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru.
5. MoHFW. National Mental Health Survey 2015-16.
6. Cochrane Library systematic reviews on postpartum depression treatment.
7. FOGSI (Federation of Obstetric and Gynaecological Societies of India).
8. Mental Healthcare Act 2017, India.